---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-054294"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2026-08-06T20:08:36+00:00"
generated_at: "2026-08-06T20:11:47.699713+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Artivion Q2 2026 revenue $125.8M (+11% YoY); net loss $(13.5M) vs prior year net income

## Summary
- Revenue $125.8M, up 11% GAAP (9% constant currency) YoY; net loss $(13.5M) or $(0.28)/share vs net income $1.3M in Q2 2025.
- Non-GAAP net income $6.3M ($0.13/share) vs $10.7M ($0.24/share) in Q2 2025; adjusted EBITDA $26.4M, up 7% YoY.
- On-X revenue grew 18% constant currency; stent grafts grew 12% constant currency; AMDS and NEXUS highlighted.
- Received U.S. FDA PMA approval for AMDS Hybrid Prosthesis; completed acquisition of Endospan Ltd. in May 2026.
- Reiterated FY2026 revenue guidance $480-496M (7-11% constant currency growth) and adjusted EBITDA $92-99M.

## SEC filing metadata
- accession: 0001628280-26-054294
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2026-08-06T20:08:36+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000162828026054294/0001628280-26-054294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000162828026054294/aort-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-054294
- JSON: https://secwatch.observer/filing/0001628280-26-054294.json
- Plain text: https://secwatch.observer/filing/0001628280-26-054294.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.